In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 37126816.
- Also identified by DOI 10.7326/J23-0025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
McCarthy MW, Naggie S, Boulware DR, et al. <b>Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial.</b> JAMA. 2023;329:296-305. 36633838.
Medical subject headings
- COVID-19
- Fluvoxamine